Quick Answer
Tempest Therapeutics, Inc. reported R&D Expense of $18.34 million for fiscal year 2017.
Tempest Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2017 | $18.34M | -15.3% |
| 2016 | $21.64M | +17.4% |
| 2015 | $18.43M | -15.4% |
| 2014 | $21.78M | +37.9% |
| 2013 | $15.80M | +149.9% |
| 2012 | $6.32M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2018 | $1.68M | -58.2% | -29.8% |
| June 30, 2018 | $2.39M | -52.1% | -8.7% |
| March 31, 2018 | $2.62M | -54.5% | -34.7% |
| September 30, 2017 | $4.02M | -19.5% | -19.6% |
| June 30, 2017 | $5.00M | -16.5% | -13.3% |
| March 31, 2017 | $5.76M | -3.2% | +15.5% |
| September 30, 2016 | $4.99M | +24.8% | -16.7% |
| June 30, 2016 | $5.99M | +48.9% | +0.5% |
- Tempest Therapeutics, Inc. showed a decrease of -15.3% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2017 period, Tempest Therapeutics, Inc.’s r&d expense has grown by 190.0% (from $6.32 million to $18.34 million).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2017 report (Form 10-K), filed with the SEC on March 15, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: